<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02866747</url>
  </required_header>
  <id_info>
    <org_study_id>16TETE04</org_study_id>
    <nct_id>NCT02866747</nct_id>
  </id_info>
  <brief_title>A Study Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and Durvalumab for Patients With Recurrent Glioblastoma</brief_title>
  <acronym>STERIMGLI</acronym>
  <official_title>A Phase I/II Multicenter Trial Evaluating the Association of Hypofractionated Stereotactic Radiation Therapy and the Anti-Programmed Death-ligand 1 (PD-L1) Durvalumab (Medi4736) for Patients With Recurrent Glioblastoma (STERIMGLI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase I/II, national, multicenter, open-label study starting with a Phase I&#xD;
      part followed by a Phase II part.&#xD;
&#xD;
      The phase I part of the study aims to evaluate the safety of the association of&#xD;
      hypofractionated stereotactic radiation therapy (hFSRT) and the anti-PD-L1 Durvalumab&#xD;
      immunotherapy in patients with recurrent glioblastoma. A maximum number of 12 patients will&#xD;
      be enrolled in this phase I part.&#xD;
&#xD;
      Once the recommended combination schema will be declared, patients will be enrolled in the&#xD;
      Phase II part of the study in order to evaluate the efficacy (overall survival) of the&#xD;
      combined treatment in recurrent glioblastoma. In this Phase II part, 100 patients will be&#xD;
      assigned by randomization to one of the two following arms:&#xD;
&#xD;
        -  Arm A (control arm): Radiation therapy alone&#xD;
&#xD;
        -  Arm B (Experimental arm): Combined treatment with Anti-PD-L1 Durvalumab&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase I: Dose Limiting Toxicities (DLT) incidence</measure>
    <time_frame>8 months</time_frame>
    <description>For each patient of the phase I part, DLT incidence will be evaluated until one month after the last radiotherapy fraction.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II: overall survival</measure>
    <time_frame>36 months post randomization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase I and II: Intracranial progression-free interval</measure>
    <time_frame>27 months</time_frame>
    <description>Intracranial progression-free interval is defined by the time from inclusion (for phase I) or randomization (for phase II) to local or distant (outside the re-irradiated volume) progression. Patients without progression at last follow-up news are censored at this date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I: Safety and tolerability according to the classification of the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.03</measure>
    <time_frame>19 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and II: Quality of life using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire (QLQ C30).</measure>
    <time_frame>27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and II : Quality of life using the using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Brain Neoplasm (QLQ-BN20).</measure>
    <time_frame>27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and II: Neurologic and neurocognitive functions using Neurologic Assessment in Neuro-Oncology (NANO) scale.</measure>
    <time_frame>27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase I and II: Neurologic and neurocognitive functions using Neurologic Assessment in Montreal Cognitive Assessment (MoCA) tests.</measure>
    <time_frame>27 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Time to Quality of Life (QoL) deterioration.</measure>
    <time_frame>27 months</time_frame>
    <description>Time to QoL deterioration is defined as the time interval between randomization and first decrease in QoL score greater or equal to 5 points. Patients without such a QoL decrease will be censored at last follow-up news or at initiation of a new therapeutic strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: time to neurocognitive deterioration</measure>
    <time_frame>27 months</time_frame>
    <description>Time to neurocognitive deterioration is defined as the time interval between randomization and first of 3 points difference in MoCA as minimal clinically important difference. Patients without such a neurocognitive decrease will be censored at last follow-up news or at initiation of a new therapeutic strategy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Immune-related intracranial progression-free interval</measure>
    <time_frame>27 months</time_frame>
    <description>Immune-related intracranial progression-free interval is defined by the time from randomization to local or distant (outside the re-irradiated volume) progression (based on immunotherapy Response Assessment for Neuro-Oncology iRANO). Patients without progression at last follow-up news are censored at this date.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Acute and late toxicities according to the classification of the National Cancer Institute Common Toxicity Criteria for Adverse Effects (NCI-CTCAE) version 4.03</measure>
    <time_frame>27 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">112</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Arm A: radiation therapy alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hypofractionated stereotactic radiation therapy (hFSRT) 24 Gray (Gy), 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 of the radiotherapy (RT), Day 3 RT and Day 5 RT.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: combined treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hFSRT 24 Gy, 8 Gy per fraction preferentially at 80% isodose (60 to 90 % accepted), 3 fractions scheduled on Day 1 RT, Day 3 RT and Day 5 RT, combined with Durvalumab infusion: first administration of Durvalumab* on Day 5 RT (i.e. the same day after the last fraction of radiation, corresponding to the Day 1 for Durvalumab treatment) and then administration of Durvalumab 1500 milligrams (mg) every four weeks.&#xD;
* Dosing 750 mg or 1500 mg, according to the recommended combination schema determined in phase I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Hypofractionated stereotactic radiation therapy</intervention_name>
    <arm_group_label>Arm A: radiation therapy alone</arm_group_label>
    <arm_group_label>Arm B: combined treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Durvalumab</intervention_name>
    <arm_group_label>Arm B: combined treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years at time of study entry.&#xD;
&#xD;
          2. Previous histopathologic confirmation of glioblastoma.&#xD;
&#xD;
          3. Any line of recurrence of glioblastoma proven by contrast enhanced Magnetic Resonance&#xD;
             Imaging (MRI) within 28 days prior to the first fraction of radiotherapy (RT), per&#xD;
             modified Response Assessment in Neuro-Oncology (RANO) criteria.&#xD;
&#xD;
             Note: Recurrence is defined as progression following therapy (i.e., chemotherapy,&#xD;
             radiation, second surgery).&#xD;
&#xD;
          4. Recurrent nodule of an histologically confirmed diagnosis of World Health Organization&#xD;
             (WHO) Grade IV malignant glioma (Glioblastoma) occurring in or out the previous&#xD;
             irradiation fields.&#xD;
&#xD;
          5. Recurrent disease documented by MRI evidence with a size of the recurrence evaluated&#xD;
             on T1 post-gadolinium sequence ≤35mm.&#xD;
&#xD;
          6. Patient for which a re-irradiation (by hFSRT) has been decided by the&#xD;
             multidisciplinary medical board.&#xD;
&#xD;
          7. Patients with measurable disease.&#xD;
&#xD;
          8. Prior radiotherapy must be ended at least 12 weeks before the first fraction of RT&#xD;
             (unless progressive disease outside of the radiation field or histopathologic&#xD;
             confirmation of unequivocal tumor to eliminate pseudoprogression images according to&#xD;
             RANO recommendations).&#xD;
&#xD;
          9. In case of previous anti-Vascular Endothelial Growth Factor (VEGF)/Vascular&#xD;
             Endothelial Growth Factor Receptor (VEGFR) targeted therapy: at least 28 days between&#xD;
             the last injection of anti-VEGF/VEGFR targeted therapy and the first fraction of RT.&#xD;
&#xD;
         10. Karnofsky performance status ≥70.&#xD;
&#xD;
         11. Adequate hematologic, renal and hepatic function, as defined below:&#xD;
&#xD;
               -  Absolute Neutrophil Count ≥ 1500/mm3&#xD;
&#xD;
               -  Haemoglobin ≥ 9.0 g/dL&#xD;
&#xD;
               -  Platelet count ≥ 100,000/mm3&#xD;
&#xD;
               -  Total bilirubin ≤ 1.5 x Upper Limit of Normal (ULN) (for patient with confirmed&#xD;
                  Gilbert's syndrome, Total bilirubin ≤ 3 x ULN)&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN&#xD;
&#xD;
               -  Creatinine ≤ 1.5 x ULN or creatinine clearance (CrCl) ≥ 40 mL/min, using the&#xD;
                  Cockcroft-Gault formula:&#xD;
&#xD;
                    -  Female CrCl = (140 - age in years) x weight in kilograms (kg) x 0.85 /72 x&#xD;
                       serum creatinine in milligram/deciliter (mg/dL)&#xD;
&#xD;
                    -  Male CrCl = (140 - age in years) x weight in kg x 1.00/72 x serum creatinine&#xD;
                       in mg/dL&#xD;
&#xD;
         12. Female Patients must either be of non-reproductive potential (i.e., post-menopausal by&#xD;
             history: ≥60 years old and no menses for ≥1 year without an alternative medical cause;&#xD;
             or history of hysterectomy, or history of bilateral tubal ligation, or history of&#xD;
             bilateral oophorectomy) or must have a negative serum pregnancy test upon study entry.&#xD;
&#xD;
         13. Written informed consent and any locally required authorization (e.g., Social security&#xD;
             for France (Health Insurance)) obtained from the patient prior performing any&#xD;
             protocol-related procedures, including screening evaluations.&#xD;
&#xD;
         14. Patient willing and able to comply with the protocol for the duration of the study&#xD;
             including undergoing treatment and scheduled visits and examinations including follow&#xD;
             up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Multifocal glioblastoma multiforme (GBM) recurrence.&#xD;
&#xD;
          2. Distance between tumor and optic ways including chiasma or brainstem &lt;1 cm.&#xD;
&#xD;
          3. Prior re-irradiation.&#xD;
&#xD;
          4. Prior exposure to Durvalumab or other anti-Programmed cell death 1(PD-1),&#xD;
             anti-Programmed death-ligand 1(PD-L1), anti-cytotoxic T-lymphocyte-associated protein&#xD;
             4 (CTLA4) antibodies.&#xD;
&#xD;
          5. Patient who received a live vaccine within 30 days prior to the first fraction of RT.&#xD;
&#xD;
          6. Receipt of the last dose of anti-cancer therapy (chemotherapy, immunotherapy,&#xD;
             endocrine therapy, targeted therapy, biologic therapy, tumor embolization, monoclonal&#xD;
             antibodies, other investigational agent) within 28 days prior to the first fraction of&#xD;
             RT.&#xD;
&#xD;
          7. Current or prior use of immunosuppressive medication within 28 days before the first&#xD;
             fraction of RT (exception: systemic corticosteroids at physiologic doses not exceeding&#xD;
             10 mg/day of prednisone or equivalent are allowed as well as steroids as premedication&#xD;
             for hypersensitivity reactions (eg, CT scan premedication) - Topical, inhaled, nasal&#xD;
             and ophthalmic steroids are not prohibited).&#xD;
&#xD;
          8. Mean QT interval corrected for heart rate (QTc) ≥470 ms calculated from 3&#xD;
             electrocardiograms (ECGs) using Fridericia's Correction&#xD;
&#xD;
          9. Presence of diffuse leptomeningeal disease or extracranial disease.&#xD;
&#xD;
         10. Active suspected or prior documented autoimmune disease (including inflammatory bowel&#xD;
             disease, celiac disease, irritable bowel syndrome, Wegener's granulomatosis and&#xD;
             Hashimoto's thyroiditis).&#xD;
&#xD;
             Note: participants with vitiligo, type I diabetes mellitus, residual hypothyroidism&#xD;
             due to autoimmune condition only requiring hormone replacement, psoriasis not&#xD;
             requiring systemic treatment, or conditions not expected to recur in the absence of an&#xD;
             external trigger, are permitted to enroll.&#xD;
&#xD;
         11. Known primary immunodeficiency or active Human Immunodeficiency Virus (HIV).&#xD;
&#xD;
         12. Known active or chronic viral hepatitis or history of any type of hepatitis within the&#xD;
             last 6 months indicated by positive test for hepatitis B surface antigen (HBV sAG) or&#xD;
             hepatitis C virus antibody.&#xD;
&#xD;
         13. History of organ transplant requiring use of immunosuppressive medication.&#xD;
&#xD;
         14. History of active tuberculosis.&#xD;
&#xD;
         15. Current pneumonitis or interstitial lung disease.&#xD;
&#xD;
         16. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable&#xD;
             angina pectoris, cardiac arrhythmia, active peptic ulcer disease or gastritis, active&#xD;
             bleeding diatheses.&#xD;
&#xD;
         17. Other invasive malignancy within 2 years prior to entry into the study, except for&#xD;
             those treated with surgical therapy only.&#xD;
&#xD;
         18. History of severe allergic reactions to any unknown allergens or any components of the&#xD;
             study drug.&#xD;
&#xD;
         19. Any prior Grade ≥ 3 immune-related adverse event (irAE) or any prior&#xD;
             corticosteroid-refractory irAE.&#xD;
&#xD;
         20. Participation in any other clinical trial involving another investigational product&#xD;
             within 4 weeks prior to the first fraction of RT.&#xD;
&#xD;
         21. Participation in any other clinical trial which delivered a dose &gt;60 Gy for the&#xD;
             primo-treatment for glioblastoma.&#xD;
&#xD;
         22. Female patients who are pregnant, breast-feeding or male or female patients of&#xD;
             reproductive potential who are not employing highly effective method of birth control.&#xD;
&#xD;
         23. Any condition that, in the clinical judgment of the investigator, is likely to prevent&#xD;
             the patient from complying with any aspect of the protocol or that may put the patient&#xD;
             at unacceptable risk.&#xD;
&#xD;
         24. Mental impairment (psychiatric illness/social situations) that may compromise the&#xD;
             ability of the patient to give informed consent and comply with the requirements of&#xD;
             the study.&#xD;
&#xD;
         25. Patient who has forfeited his/her freedom by administrative or legal award or who is&#xD;
             under guardianship.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Elizabeth COHEN-JONATHAN MOYAL, MD, PhD</last_name>
    <phone>+33 5 31 15 99 07</phone>
    <email>moyal.elizabeth@iuct-oncopole.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Muriel MOUNIER, PharmD</last_name>
    <phone>+33 5 31 15 58 96</phone>
    <email>mounier.muriel@iuct-oncopole.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancerologie de L'Ouest</name>
      <address>
        <city>Angers</city>
        <zip>49055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maud AUMONT, MD</last_name>
      <phone>02 40 67 99 00</phone>
      <email>Maud.aumont@ico.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hopital Avicenne</name>
      <address>
        <city>Bobigny</city>
        <zip>93 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antoine CARPENTIER, MD</last_name>
      <phone>+33 1 48 95 54 01</phone>
      <email>antoine.carpentier@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine CARPENTIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul LESUEUR, MD</last_name>
      <phone>02 31 45 50 20</phone>
      <email>p.lesueur@baclesse.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Georges Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21 000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles TRUC, MD</last_name>
      <phone>+33 3 80 73 75 18</phone>
      <email>gtruc@cgfl.fr</email>
    </contact>
    <investigator>
      <last_name>Gilles TRUC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Regional Du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34 298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie CHARISSOUX, MD</last_name>
      <phone>+33 4 67 61 37 16</phone>
      <email>marie.charissoux@icm.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Marie CHARISSOUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Pitie Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Loïc FEUVRET, MD</last_name>
      <phone>+33 1 42 17 81 60</phone>
      <email>loic.feuvret@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Loïc FEUVRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92 210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia MOISSON, MD</last_name>
      <phone>01 41 11 15 15</phone>
      <email>patricia.moisson@curie.fr</email>
    </contact>
    <investigator>
      <last_name>Patricia MOISSON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georges NOEL, MD</last_name>
      <phone>+33 3 88 25 24 78</phone>
      <email>gnoel@strasbourg.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Georges NOEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth COHEN-JONATHAN MOYAL, MD, PhD</last_name>
      <phone>+ 33 5 31 15 99 07</phone>
      <email>moyal.elizabeth@iuct-oncopole.fr</email>
    </contact>
    <investigator>
      <last_name>Elizabeth MOYAL-JONATHAN COHEN, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94 800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Frédéric D'HERMAIN, MD</last_name>
      <phone>+33 1 42 11 62 20</phone>
      <email>Frederic.dhermain@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Frédéric D'HERMAIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 5, 2016</study_first_submitted>
  <study_first_submitted_qc>August 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 15, 2016</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Durvalumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

